US Bancorp DE Has $8.78 Million Holdings in EXACT Sciences Co. (EXAS)

US Bancorp DE cut its position in shares of EXACT Sciences Co. (NASDAQ:EXAS) by 1.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,268 shares of the medical research company’s stock after selling 1,152 shares during the period. US Bancorp DE owned approximately 0.09% of EXACT Sciences worth $8,781,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of EXAS. Xact Kapitalforvaltning AB raised its stake in shares of EXACT Sciences by 4.5% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 18,725 shares of the medical research company’s stock valued at $1,478,000 after acquiring an additional 800 shares during the period. IFP Advisors Inc raised its stake in shares of EXACT Sciences by 49.4% in the 3rd quarter. IFP Advisors Inc now owns 6,192 shares of the medical research company’s stock valued at $489,000 after acquiring an additional 2,047 shares during the period. First Mercantile Trust Co. raised its stake in shares of EXACT Sciences by 8.2% in the 2nd quarter. First Mercantile Trust Co. now owns 29,766 shares of the medical research company’s stock valued at $1,779,000 after acquiring an additional 2,261 shares during the period. GSA Capital Partners LLP raised its stake in shares of EXACT Sciences by 30.2% in the 2nd quarter. GSA Capital Partners LLP now owns 10,683 shares of the medical research company’s stock valued at $639,000 after acquiring an additional 2,477 shares during the period. Finally, Fulton Bank N.A. purchased a new stake in shares of EXACT Sciences in the 3rd quarter valued at approximately $208,000. 87.06% of the stock is currently owned by institutional investors.

Shares of EXAS stock opened at $74.62 on Friday. The company has a debt-to-equity ratio of 0.94, a current ratio of 12.08 and a quick ratio of 11.72. EXACT Sciences Co. has a fifty-two week low of $37.36 and a fifty-two week high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. The firm had revenue of $118.29 million during the quarter, compared to analysts’ expectations of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The business’s quarterly revenue was up 63.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.23) earnings per share. On average, sell-side analysts predict that EXACT Sciences Co. will post -1.53 EPS for the current year.

In related news, Director Michael S. Wyzga sold 2,468 shares of EXACT Sciences stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the transaction, the director now owns 9,112 shares in the company, valued at $682,033.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Graham Peter Lidgard sold 79,673 shares of EXACT Sciences stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $71.73, for a total transaction of $5,714,944.29. Following the completion of the transaction, the insider now owns 124,528 shares of the company’s stock, valued at approximately $8,932,393.44. The disclosure for this sale can be found here. Insiders sold 218,255 shares of company stock valued at $15,791,740 in the last 90 days. Company insiders own 3.20% of the company’s stock.

EXAS has been the topic of a number of research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $76.00 price target (up from $67.00) on shares of EXACT Sciences in a research note on Wednesday, July 18th. Bank of America boosted their price target on shares of EXACT Sciences from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Monday, July 23rd. BidaskClub downgraded shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th. Craig Hallum reduced their price target on shares of EXACT Sciences from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 2nd. Finally, Jefferies Financial Group reduced their price target on shares of EXACT Sciences from $60.00 to $57.00 and set a “buy” rating on the stock in a research note on Thursday, August 2nd. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. EXACT Sciences has a consensus rating of “Buy” and a consensus target price of $84.08.

TRADEMARK VIOLATION NOTICE: “US Bancorp DE Has $8.78 Million Holdings in EXACT Sciences Co. (EXAS)” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/10/us-bancorp-de-has-8-78-million-holdings-in-exact-sciences-co-exas.html.

EXACT Sciences Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: Outstanding Shares

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply